Item 8.01 Other Events.



On August 22, 2022, Travere Therapeutics, Inc. (the "Company") and CSL Vifor
(formerly known as Vifor (International)) announced that the European Medicines
Agency ("EMA") has accepted for review the conditional marketing authorization
application of sparsentan for the treatment of IgA nephropathy ("IgAN"). A
review decision is expected in the second half of 2023.

Forward-Looking Statements



This Current Report on Form 8-K contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include the timing of the EMA's review decision and
the outcome of that decision. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties, including
factors that could delay, divert or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among the factors that could cause
actual results to differ materially from those indicated in the forward-looking
statements are risks and uncertainties associated with the regulatory review and
approval process, including the conditional marketing authorization approval
pathway. There is no guarantee that the EMA will provide a review decision on
the timeline expected or that it will grant conditional marketing authorization
of sparsentan for IgAN or that sparsentan will be approved at all. In addition,
such risks and uncertainties may include those described in the Company's
filings with the Securities and Exchange Commission, including under the "Risk
Factors" heading of the Company's quarterly report on Form 10-Q for the quarter
ended June 30, 2022, as filed with the SEC on August 4, 2022. You are cautioned
not to place undue reliance on any forward-looking statements as there are
important factors that could cause actual results to differ materially from
those in any forward-looking statements, many of which are beyond our control.
Except to the extent required by law, the Company undertakes no obligation to
publicly update any forward-looking statement.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description


      104              Cover Page Interactive Data File (embedded within the Inline XBRL document).






--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: August 22, 2022                                                 By: 

/s/ Elizabeth E. Reed

Name: Elizabeth E. Reed

Senior Vice President, General

Title: Counsel and Secretary

© Edgar Online, source Glimpses